1. Bernal W, Smith HM, Williams R. A community prevalence study of antibodies to hepatitis A and E in inner-city London. J Med Virol. 1996;49(3):230-4. [
DOI:10.1002/(SICI)1096-9071(199607)49:33.0.CO;2-G]
2. Drexler JF, Corman VM, Lukashev AN, van den Brand JM, Gmyl AP, Brunink S, et al. Evolutionary origins of hepatitis A virus in small mammals. Proc Natl Acad Sci U S A. 2015;112(49):15190-5. [
DOI:10.1073/pnas.1516992112] [
PMID] [
PMCID]
3. Xing L, Li TC, Mayazaki N, Simon MN, Wall JS, Moore M, et al. Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem. 2010;285(43):33175-83. [
DOI:10.1074/jbc.M110.106336] [
PMID] [
PMCID]
4. Purcell RH, Emerson SU. Hepatitis E: an emerging awareness of an old disease. J Hepatol. 2008;48(3):494-503. [
DOI:10.1016/j.jhep.2007.12.008] [
PMID]
5. Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med. 1985;313(17):1059-67. [
DOI:10.1056/NEJM198510243131706] [
PMID]
6. Gallian P, Piquet Y, Assal A, Djoudi R, Chiaroni J, Izopet J, et al. [Hepatitis E virus: Blood transfusion implications]. Transfus Clin Biol. 2014;21(4-5):173-7. [
DOI:10.1016/j.tracli.2014.07.007] [
PMID]
7. Lee EJ, Kwon SY, Seo TH, Yun HS, Cho HS, Kim BK, et al. [Clinical features of acute hepatitis A in recent two years]. Korean J Gastroenterol. 2008;52(5):298-303.
8. Risalde MA, Rivero-Juarez A, Romero-Palomo F, Frias M, Lopez-Lopez P, Cano-Terriza D, et al. Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar. PLoS ONE. 2017;12(11):e0186858. [
DOI:10.1371/journal.pone.0186858] [
PMID] [
PMCID]
9. Belei O, Ancusa O, Mara A, Olariu L, Amaricai E, Folescu R, et al. Current Paradigm of Hepatitis E Virus Among Pediatric and Adult Patients. Front Pediatr. 2021;9(1032):721918. [
DOI:10.3389/fped.2021.721918] [
PMID] [
PMCID]
10. Webb GW, Kelly S, Dalton HR. Hepatitis A and Hepatitis E: Clinical and Epidemiological Features, Diagnosis, Treatment, and Prevention. Clin Microbiol Newsl. 2020;42(21):171-9. [
DOI:10.1016/j.clinmicnews.2020.10.001] [
PMID] [
PMCID]
11. Haeri Mazanderani A, Motaze NV, McCarthy K, Suchard M, du Plessis NM. Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005-2015. PLoS ONE. 2019;14(6):e0216033. [
DOI:10.1371/journal.pone.0216033] [
PMID] [
PMCID]
12. Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379(9835):2477-88. [
DOI:10.1016/S0140-6736(11)61849-7]
13. Ndumbi P, Freidl GS, Williams CJ, Mardh O, Varela C, Avellon A, et al. Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European :union: and European Economic Area, June 2016 to May 2017. Euro Surveill. 2018;23(33).
14. Khuroo MS, Khuroo MS, Khuroo NS. Transmission of Hepatitis E Virus in Developing Countries. Viruses. 2016;8(9):253. [
DOI:10.3390/v8090253] [
PMID] [
PMCID]
15. Hesamizadeh K, Sharafi H, Keyvani H, Alavian SM, Najafi-Tireh Shabankareh A, Sharifi Olyaie R, et al. Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran. Hepat Mon. 2016;16(1):e32215. [
DOI:10.5812/hepatmon.32215]
16. Hoseini SG, Kelishadi R, Ataei B, Yaran M, Motlagh ME, Ardalan G, et al. Seroprevalence of hepatitis A in Iranian adolescents: is it time to introduce a vaccine? Epidemiol Infect. 2016;144(2):291-6. [
DOI:10.1017/S0950268815001302] [
PMID]
17. Izadi M, Esfahani AA, Hassannia H, Jafari NJ, Najarkolaei FR, Rezaee-Zavareh MS. Seroprevalence of hepatitis A virus among Iranian soldiers. Gastroenterol Hepatol Bed Bench. 2016;9(2):100.
18. Behzadifar M, Lankarani KB, Abdi S, Taheri Mirghaed M, Beyranvand G, Keshavarzi A, et al. Seroprevalence of Hepatitis E Virus in Iran: A Systematic Review and Meta-analysis. Middle East J Dig Dis. 2016;8(3):189-200. [
DOI:10.15171/mejdd.2016.31] [
PMID] [
PMCID]
19. Alavian SM. Occult hepatitis B virus infection among hemodialysis patients. Hepat Mon. 2012;12(4):242-3.
https://doi.org/10.5812/hepatmon.869 [
DOI:10.5812/hepatmon.6226] [
PMID] [
PMCID]
20. Ghasemian R, Babamahmoodi F, Ahangarkani F. Hepatitis A Is a Health Hazard for Iranian Pilgrims Who Go to Holly Karbala: A Preliminary Report. Hepat Mon. 2016;16(6):e38138. [
DOI:10.5812/hepatmon.38138] [
PMID] [
PMCID]
21. Alian S, Ajami A, Ghasemian R, Yadegarinia D. Age-specific seroprevalence of hepatitis A in Sari, northern Islamic Republic of Iran. East Mediterr Health J. 2011;17(10):754-8. [
DOI:10.26719/2011.17.10.754] [
PMID]
22. Saffar MJ, Farhadi R, Ajami A, Khalilian AR, Babamahmodi F, Saffar H. Seroepidemiology of hepatitis E virus infection in 2-25-year-olds in Sari district, Islamic Republic of Iran. East Mediterr Health J. 2009;15(1):136-42. [
DOI:10.26719/2009.15.1.136] [
PMID]
23. Tahamtan A, Moradi A, Ghaemi A, Kelishadi M, Ghafari H, Hashemi P, et al. Seroepidemiology of Hepatitis E Virus in hemodialysis patients in Gorgan-Iran. Med Lab J. 2013;7(2):13-7.
24. Merat S, Rezvan H, Nouraie M, Abolghasemi H, Jamali R, Amini-Kafiabad S, et al. Seroprevalence and risk factors of hepatitis A virus infection in Iran: a population based study. Arch Iran Med. 2010;13(2):99-104.
25. Mohebbi SR, Rostami Nejad M, Tahaei SM, Pourhoseingholi MA, Habibi M, Azimzadeh P, et al. Seroepidemiology of hepatitis A and E virus infections in Tehran, Iran: a population based study. Trans R Soc Trop Med Hyg. 2012;106(9):528-31. [
DOI:10.1016/j.trstmh.2012.05.013] [
PMID]
26. Elikaei A, Sharifi Z, Shooshtari MM, Hosseini M, Maroufi Y. Prevalence of HAV among healthy blood donors referring to Tehran transfusion center. Iran J Public Health. 2008;37(4):126-30.
27. Ramezani H, Bozorgi S, Nooranipour M, Mostajeri A, Kargar-Fard H, Molaverdikhani S, et al. Prevalence and risk factors of hepatitis A among blood donors in Qazvin, central Iran. Singapore Med J. 2011;52(2):107-12.
28. Assarehzadegan MA, Shakerinejad G, Amini A, Rezaee SA. Seroprevalence of hepatitis E virus in blood donors in Khuzestan Province, southwest Iran. Int J Infect Dis. 2008;12(4):387-90. [
DOI:10.1016/j.ijid.2007.09.015] [
PMID]
29. Aminiafshar S, Alimagham M, Gachkar L, Yousefi F, Attarchi Z. Anti hepatitis E virus seropositivity in a group of blood donors. Iran J Public Health. 2004;33(4):53-6.
30. Taremi M, Gachkar L, MahmoudArabi S, Kheradpezhouh M, Khoshbaten M. Prevalence of antibodies to hepatitis E virus among male blood donors in Tabriz, Islamic Republic of Iran. East Mediterr Health J. 2007;13:98-102.
31. Ehteram H, Ramezani A, Eslamifar A, Sofian M, Banifazl M, Ghassemi S, et al. Seroprevalence of Hepatitis E Virus infection among volunteer blood donors in central province of Iran in 2012. Iran J Microbiol. 2013;5(2):172.
32. Johargy AK, Mahomed MF, Khan MM, Kabrah S. Anti hepatitis E virus seropositivity in a group of male blood donors in Makkah, Saudi Arabia. J Pak Med Assoc. 2013;63(2):185-9.
33. Petrovic T, Lupulovic D, Jimenez de Oya N, Vojvodic S, Blazquez AB, Escribano-Romero E, et al. Prevalence of hepatitis E virus (HEV) antibodies in Serbian blood donors. J Infect Dev Ctries. 2014;8(10):1322-7. [
DOI:10.3855/jidc.4369] [
PMID]
34. Koroglu M, Jacobsen KH, Demiray T, Ozbek A, Erkorkmaz U, Altindis M. Socioeconomic indicators are strong predictors of hepatitis A seroprevalence rates in the Middle East and North Africa. J Infect Public Health. 2017;10(5):513-7. [
DOI:10.1016/j.jiph.2016.09.020] [
PMID]
35. Cardenas A, Smit E, Bethel JW, Houseman EA, Kile ML. Arsenic exposure and the seroprevalence of total hepatitis A antibodies in the US population: NHANES, 2003-2012. Epidemiol Infect. 2016;144(8):1641-51. [
DOI:10.1017/S0950268815003088] [
PMID] [
PMCID]
36. Carrillo-Santisteve P, Tavoschi L, Severi E, Bonfigli S, Edelstein M, Bystrom E, et al. Seroprevalence and susceptibility to hepatitis A in the European :union: and European Economic Area: a systematic review. Lancet Infect Dis. 2017;17(10):e306-e19. [
DOI:10.1016/S1473-3099(17)30392-4]
37. Khojah A, Felimban R, Kabrah S, Alqasmi M. Prevalence of Kell Blood Group System in Blood Donors of Makkah City, Saudi Arabia. Clin Lab. 2021;67(6). [
DOI:10.7754/Clin.Lab.2020.200946]